Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 2/20 | 0.50 |
| ▸ | HTR6 | P50406 | 2/20 | 0.48 |
| ▸ | MAPK14 | Q16539 | 11/20 | 0.47 |
| ▸ | CSNK1D | P48730 | 2/20 | 0.43 |
| ▸ | CSNK1E | P49674 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL989405 | 0.84 | MAPK14 (0.53) | MAPK14CSNK1DCSNK1ECYP3A4 | |
| SCHEMBL989245 | 0.75 | MAPK14 (0.47) | MAPK14CYP3A4CYP2C9 | |
| SCHEMBL4063490 | 0.74 | PRKCQ (0.44) | MAPK14 | |
| SCHEMBL3989220 | 0.73 | MAPK14 (0.52) | MAPK14CSNK1DCSNK1EMAPTCYP1A2 | |
| SCHEMBL3997933 | 0.73 | MAPK14 (0.51) | MAPK14CSNK1DCSNK1E | |
| SCHEMBL989125 | 0.72 | MAPK14 (0.46) | MAPK14MAPTCYP1A2CYP2C19NPSR1 | |
| SCHEMBL18104347 | 0.71 | APP (0.70) | APPHTR6MAPTCYP1A2CYP3A4 | |
| SCHEMBL12684854 | 0.71 | APP (0.70) | APPHTR6MAPTCYP1A2CYP3A4 | |
| SCHEMBL12684866 | 0.71 | APP (0.58) | APPHTR6MAPTCYP1A2CYP3A4 | |
| SCHEMBL989296 | 0.70 | MAPK14 (0.52) | MAPK14CSNK1DCSNK1ECYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7863310-B2 | Kinase inhibitors | ELI LILLY AND COMPANY (US) | 2011-01-04 | — | — | US | disclosed |
| US-20080227839-A1 | Kinase Inhibitors | ELI LILLY AND COMPANY | 2008-09-18 | — | — | US | disclosed |
| EP-1720862-A1 | KINASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2006-11-15 | — | — | EP | disclosed |
| WO-2005080380-A1 | KINASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2005-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080227839-A1 | Kinase Inhibitors | ABL1, MAP3K20, MAP3K19 | APP 4620/4885HTR6 4089/4885MAPK14 341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.